382MO Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

• DOI: 10.1016/j.annonc.2023.09.559
• Publication Date: 2023-10-20T11:33:40Z
• Authors: N.U. Lin; V.F. Borges; M.R. Patel; M. Okera; J. Meisel; R. Wesolowski; T. Pluard; K.D. Miller; N.J. McCarthy; A.K. Conlin; R. Mahtani; D. Sabanathan; K.E. McCann; E. Roesch; G. Mathauda-Sahota; J. Schroeder; E.P. Hamilton
• Keywords: Fulvestrant